Annexon, Inc.

Stage 4 · Declining · week 7

As of Oct 22, 2026, Annexon is in Stage 4, the downtrend phase, now in week 7 (since Sep 10, 2026). It closed at $3.81, 45.3% below its 52-week high and below its 200-day average, which is falling.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. More about the company

$3.81

-2.54% today

$722M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ANNX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 16w

S2 15w

S2 19w

S4 23w

S2 23w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 16w → S1 7w → S2 15w → S3 10w → S2 19w → S3 5w → S4 23w → S1 10w → S4 4w → S1 3w → S2 23w → S3 4w → S2 5w → S3 12w → S2 1w → S1 1w → S4 6w current

Total tracked: 165 weeks across 17 stage runs.

ANNX among Biotechnology132nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…132	ANNXAnnexon, Inc.	Stage 4 · wk 7	71	−1.6%

vs 52W High

-45.3%

$2.68 lo$6.96 hi

45.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 7

1w13w26w

Week 7, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-27.8%

200 DMA: $5.28 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.12x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-1.6%

-27.0%

-37.1%

YTD

-18.8%

+21.7%

Scan Membership

Breakout Watch

Latest: 2024-07-17

4 appearances in last 60 days. First seen: 2022-09-23.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 7 · Vol 1.12x

2026-10-21S4

Wk 6 · Vol 1.44x

2026-10-20S4

Wk 6 · Vol 2.05x

2026-10-19S4

Wk 6 · Vol 2.10x

2026-10-16S4

Wk 6 · Vol 1.76x

2026-10-15S4

Wk 6 · Vol 0.90x

2026-10-14S4

Wk 5 · Vol 1.38x

2026-10-13S4

Wk 5 · Vol 1.17x

2026-10-12S4

Wk 5 · Vol 0.66x

2026-10-09S4

Wk 5 · Vol 0.81x

2026-10-08S4

Wk 5 · Vol 1.09x

2026-10-07S4

Wk 4 · Vol 0.83x

Moving averages & range

50 DMA

$4.37

200 DMA

$5.28

52W High

$6.96

52W Low

$2.68

5D Low

$3.41

Resistance levels (recent highs)

20d High

$4.23

60d High

$5.60

120d High

$6.50

250d High

$6.96

Next resistance

+11.0%

to 20d High

ROE

-105.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.6

Annexon: quick answers

What stage is Annexon in?

As of Oct 22, 2026, Annexon (ANNX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 10, 2026 and is in week 7. What the four stages mean

Is Annexon in an uptrend?

No. Annexon is in a Stage 4 downtrend. It trades 27.8% below its 200-day average, which is falling.

How far is Annexon from its 52-week high?

Annexon closed at $3.81 on Oct 22, 2026, 45.3% below its 52-week high of $6.96. Its 52-week low is $2.68.

How has Annexon performed over the past year?

As of Oct 22, 2026, Annexon is up 21.7% over the past year and down 18.8% so far in 2026.

Which sector and industry is Annexon in?

Annexon is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.